Targeting mTOR with rapamycin: one dose does not fit all - Wikidata - awgldk - TriplyDB

Targeting mTOR with rapamycin: one dose does not fit all

Targeting mTOR with rapamycin: one dose does not fit all

http://www.wikidata.org/entity/Q37409171

about

Updates of mTOR inhibitors Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony Caloric restriction: is mammalian life extension linked to p53?Emerging roles of PDGF-D in EMT progression during tumorigenesis Mechanisms of drug resistance in kinases.Role of the mammalian target of rapamycin pathway in lentiviral vector transduction of hematopoietic stem cells Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat The Complex Roles of Mechanistic Target of Rapamycin in Adipocytes and Beyond.Development of a Whole Organism Platform for Phenotype-Based Analysis of IGF1R-PI3K-Akt-Tor Action.Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.Engineered allosteric activation of kinases in living cells.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice.Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo.Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells.Reduced mortality and moderate alcohol consumption: the phospholipase D-mTOR connection Telomerase expression abrogates rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells.MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors.Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma Rapamycin inhibits the production of myofibroblasts and reduces corneal scarring after photorefractive keratectomy.The role of hypothalamic mTORC1 signaling in insulin regulation of food intake, body weight, and sympathetic nerve activity in male mice.High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling.Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice.Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts.Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice The Enigma of Rapamycin Dosage.mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.5-Aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells.Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy Microbial synthesized biodegradable PHBHHxPEG hybrid copolymer as an efficient intracellular delivery nanocarrier for kinase inhibitor.Rapamycin Prolongs the Survival of Corneal Epithelial Cells in Culture.Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells Natural product scaffolds as leads to drugs.Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.The mTOR protein as a target in thyroid cancer.The promise of mTOR inhibitors in the treatment of colorectal cancer.

P2860

Q24607170-60A16D09-B3B9-4354-8D68-395894147CED Q24629514-02046CB7-F739-464D-BFB6-39EFC472CE15 Q26829232-CF4BD330-F6AB-4B78-BC91-13CB680584ED Q26859634-2FA14257-2C98-45F7-AAC5-57B675AB544B Q27692567-6DB04E69-994C-4FD2-B8CD-A8A499605D65 Q28082153-A2D3FF12-77DE-4508-8F1C-8477F2D3D40D Q28573157-C2DB27E4-D13A-4291-B6F4-193D3DAA9322 Q30235555-B5A6C7E2-68AA-43CA-AD55-A013B8A155D4 Q30356087-2AF54CED-3A7A-4EE8-BCBB-D0473DA8EC10 Q33493174-5FACF1A5-C1BA-414D-83C1-B5F97AB36DF1 Q33987463-BB709943-9AC8-4F66-BE4D-5DD33C0F1A87 Q34024558-5FDB7FE7-592F-4767-BB33-21D1D48D7DE7 Q34028756-3336B2A4-822C-4A6F-976A-89211B49F472 Q34078704-0A3023DD-EA04-419A-8BAC-34A1F6838E57 Q34196369-C24A2DFF-8EA5-4607-B0D5-5F119DE970B6 Q34213257-F6498DBC-3CC6-4FAD-B0EB-931FA0CA515A Q34418102-0FF6FE09-143C-42A3-A89E-ED357BA6C816 Q34957090-BE4F5538-6AC8-413E-ADC8-7F2050257F55 Q34977124-7C747F21-64B1-48F6-84DA-7217E23D56EE Q35012339-CBE09E3F-BF73-4EE6-A5A5-5099AADB2A2C Q35442466-4DDFCCA7-6DF3-4ABC-88C2-B400F7B50A4B Q35694634-55077D3B-3478-461D-9F56-987A7ADA332A Q36121394-819AE1F7-DC13-4704-9EC2-3CCD94408606 Q36338250-2735EF1C-C4C8-49E9-96CB-1DB1ECCD02C3 Q36353626-67F6FBE8-5628-4022-ACFE-93513921BF78 Q36544718-60CB39A9-52F8-48A9-8C93-5E81F49AC466 Q36664900-14FAD8DC-2770-4DB2-B53D-70EE30352E42 Q36745445-10D658ED-DA82-4375-9369-766EEECB8E22 Q36780632-86195CFF-15C6-4B0F-8F14-07A6A0E66538 Q36801990-4C7656A4-C806-4D1C-AEA5-70EB7DE6764F Q37192602-9EEA1542-9ABE-4F75-A1B6-1801BF7683D4 Q37192611-3139B6AA-474D-408A-B46C-A37F71AAED97 Q37192616-B5A08455-77C9-404B-9320-851905AD4874 Q37539595-E6214092-BABD-4D1C-8E60-F67BC126E92A Q37561446-99A47CD8-E415-431A-91F7-75C35EE47B25 Q37640929-6790690F-43B1-49FD-8E0F-C2B700AA6C67 Q37855860-C7256A51-923E-43F6-A870-C0219E249618 Q37871915-8463E5D4-DED6-4DCF-8641-C4F841A894E1 Q37894106-85221A7B-1816-42A0-84C4-A70C627FD544 Q38043507-9B1EABBF-C507-4DEF-87EE-B3EC26106712

P2860

Targeting mTOR with rapamycin: one dose does not fit all

http://www.wikidata.org/entity/Q37409171

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting mTOR with rapamycin: one dose does not fit all

@en

Targeting mTOR with rapamycin: one dose does not fit all.

@nl

type

label

Targeting mTOR with rapamycin: one dose does not fit all

@en

Targeting mTOR with rapamycin: one dose does not fit all.

@nl

prefLabel

Targeting mTOR with rapamycin: one dose does not fit all

@en

Targeting mTOR with rapamycin: one dose does not fit all.

@nl

P1433

Q37409171-EA339772-AB05-4BAD-AFDB-591148811107

P1476

Q37409171-10744D1A-7BD6-471B-AAFE-C83A5D904645

P2093

Q37409171-28C0C31B-7343-44F6-B508-F5CB4E34E81C

Q37409171-D8F48BA4-4AC7-4135-9704-A85A09BD3427

P2860

Q37409171-0DEE2F5E-3018-4B64-9959-77BE4583C212

Q37409171-12399BA3-F1CB-4673-BFBC-E6FD10D534CB

Q37409171-1C342752-4B5E-4AC1-A6B6-3E4960D68723

Q37409171-29379388-7AF0-4EF9-8BA7-6D87B2855553

Q37409171-2AD58C4A-0D84-44EA-BCE7-ED3F11CB217E

Q37409171-3483E997-3F03-4BF2-9E3A-3803E223CD90

Q37409171-4801D0FE-49E2-46C4-9D06-33402D5CA2F1

Q37409171-4B2651F3-1303-454D-88D7-0B38C137A02B

Q37409171-513A68B2-FD6C-418F-9D30-60D322F5DD4B

Q37409171-7A91C70D-5E60-44E3-9414-C88E60ADC849

P304

Q37409171-517B5BD1-0FBE-44E3-B876-5CE92AFAD03B

P31

Q37409171-1A1446C2-2F48-4AB5-A9EB-220549879E00

P356

Q37409171-63A81D48-BC8D-4DF3-81F4-55861203C99B

P433

Q37409171-CD251C7F-457D-4025-910B-F91566509B74

P478

Q37409171-3939B954-9059-4328-AEA5-2E470A8E7EF8

P577

Q37409171-9C038F0C-2830-4EE2-95D7-D3E6D88BE4B5

P5875

Q37409171-96C9CFD4-C7B5-418A-A679-4C63A566D087

P698

Q37409171-0BED1B4B-B8F3-4C5B-BC47-F9CDABF9D109

P932

Q37409171-522FCDB9-9FE3-4C58-8375-DA4324237950

P356

P1433

P1476

Targeting mTOR with rapamycin: one dose does not fit all

@en

P2093

Alfredo Toschi

http://www.w3.org/2001/XMLSchema#string

David A Foster

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR

Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo

Phosphatidic acid-mediated mitogenic activation of mTOR signaling

Defining the role of mTOR in cancer

mTOR and cancer therapy

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

P304

1026-1029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.8.7.8044

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24185996

http://www.w3.org/2001/XMLSchema#string

P698

19270529

http://www.w3.org/2001/XMLSchema#string

P932

2778016

http://www.w3.org/2001/XMLSchema#string